JP2019532928A5 - - Google Patents

Download PDF

Info

Publication number
JP2019532928A5
JP2019532928A5 JP2019515241A JP2019515241A JP2019532928A5 JP 2019532928 A5 JP2019532928 A5 JP 2019532928A5 JP 2019515241 A JP2019515241 A JP 2019515241A JP 2019515241 A JP2019515241 A JP 2019515241A JP 2019532928 A5 JP2019532928 A5 JP 2019532928A5
Authority
JP
Japan
Prior art keywords
alkyl
alkoxy
heteroaryl
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019515241A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019532928A (ja
JP6997178B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/051692 external-priority patent/WO2018053215A1/en
Publication of JP2019532928A publication Critical patent/JP2019532928A/ja
Publication of JP2019532928A5 publication Critical patent/JP2019532928A5/ja
Priority to JP2021203942A priority Critical patent/JP7281527B2/ja
Application granted granted Critical
Publication of JP6997178B2 publication Critical patent/JP6997178B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019515241A 2016-09-16 2017-09-15 ベータラクタマーゼ阻害剤化合物 Active JP6997178B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021203942A JP7281527B2 (ja) 2016-09-16 2021-12-16 ベータラクタマーゼ阻害剤化合物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662395464P 2016-09-16 2016-09-16
US62/395,464 2016-09-16
US201762456423P 2017-02-08 2017-02-08
US62/456,423 2017-02-08
PCT/US2017/051692 WO2018053215A1 (en) 2016-09-16 2017-09-15 Beta-lactamase inhibitor compounds

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021203942A Division JP7281527B2 (ja) 2016-09-16 2021-12-16 ベータラクタマーゼ阻害剤化合物

Publications (3)

Publication Number Publication Date
JP2019532928A JP2019532928A (ja) 2019-11-14
JP2019532928A5 true JP2019532928A5 (enExample) 2020-10-01
JP6997178B2 JP6997178B2 (ja) 2022-02-03

Family

ID=60083416

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019515241A Active JP6997178B2 (ja) 2016-09-16 2017-09-15 ベータラクタマーゼ阻害剤化合物
JP2021203942A Active JP7281527B2 (ja) 2016-09-16 2021-12-16 ベータラクタマーゼ阻害剤化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021203942A Active JP7281527B2 (ja) 2016-09-16 2021-12-16 ベータラクタマーゼ阻害剤化合物

Country Status (23)

Country Link
US (1) US10800778B2 (enExample)
EP (1) EP3512851B1 (enExample)
JP (2) JP6997178B2 (enExample)
KR (2) KR102537340B1 (enExample)
CN (2) CN114591223B (enExample)
AU (1) AU2017325863B2 (enExample)
CA (1) CA3036557A1 (enExample)
DK (1) DK3512851T3 (enExample)
ES (1) ES2927986T3 (enExample)
HR (1) HRP20221217T1 (enExample)
HU (1) HUE060282T2 (enExample)
IL (2) IL289686B2 (enExample)
LT (1) LT3512851T (enExample)
MA (1) MA46242A (enExample)
MX (2) MX385507B (enExample)
PH (1) PH12019500558B1 (enExample)
PL (1) PL3512851T3 (enExample)
PT (1) PT3512851T (enExample)
SG (1) SG11201901658PA (enExample)
SI (1) SI3512851T1 (enExample)
SM (1) SMT202200397T1 (enExample)
TW (1) TWI773687B (enExample)
WO (1) WO2018053215A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA124464C2 (uk) 2016-06-30 2021-09-22 Кьюпекс Біофарма, Інк. Похідні боронової кислоти та їх терапевтичні застосування
KR102537340B1 (ko) * 2016-09-16 2023-05-26 엔타시스 테라퓨틱스 리미티드 베타-락타마제 억제제 화합물
MA48743A (fr) 2017-05-08 2020-04-08 Entasis Therapeutics Inc Composés et méthodes de traitement d'infections bactériennes
WO2019204419A1 (en) 2018-04-20 2019-10-24 The Medicines Company (San Diego), Llc Boronic acid derivatives and therapeutic uses thereof
CA3110111A1 (en) 2018-08-09 2020-02-13 Antabio Sas Diazabicyclooctanones as inhibitors of serine beta-lactamases
US11905286B2 (en) 2018-08-09 2024-02-20 Antabio Sas Diazabicyclooctanones as inhibitors of serine beta-lactamases
CN112209928B (zh) * 2019-07-10 2023-02-17 华东理工大学 共价键标记丝氨酸类beta-内酰胺酶的试剂及制备和应用
CN110898999A (zh) * 2019-11-26 2020-03-24 中国矿业大学 一种煤焦油基煤泥浮选药剂及其制备方法
AU2021266715A1 (en) 2020-05-05 2022-11-17 Qpex Biopharma, Inc. Boronic acid derivatives and synthesis, polymorphic forms, and therapeutic uses thereof
CN111790439B (zh) * 2020-07-29 2022-12-27 成都能特科技发展有限公司 一种手性二级胺二苯基膦芳甲酰胺双功能催化剂及其制备方法与应用
EP4146650B1 (en) 2020-09-01 2026-01-21 Ningxia Academy of Agriculture and Forestry Sciences Beta-lactamase inhibitors and their preparation
CN117157078A (zh) * 2021-04-05 2023-12-01 Qpex生物制药有限公司 头孢布烯给药方案
EP4146651B1 (en) 2021-05-07 2026-03-04 Ningxia Academy of Agriculture and Forestry Sciences Sulfonylamidine substituted compounds and their use as beta-lactamase inhibitors
US11814385B2 (en) * 2021-06-25 2023-11-14 University Of South Florida Small molecule inhibitors targeting Clostridioides difficile sporulation
WO2023206580A1 (en) 2022-04-29 2023-11-02 Entasis Therapeutics Limited Durlobactam crystalline forms
US20230398101A1 (en) * 2022-06-09 2023-12-14 Fleurir Abx Llc Co-agents as Therapy Against Anaerobic Pathogens
CN118271319B (zh) * 2022-12-30 2025-02-28 成都四面体药物研究有限公司 一种β-内酰胺酶抑制剂含脲双环化合物、其制备方法及其用途
CN118772145B (zh) * 2023-04-04 2025-10-10 上海医药工业研究院有限公司 一种二氮杂双环辛烯化合物的制备方法
CN116693531A (zh) * 2023-06-09 2023-09-05 河南师范大学 一种桥联多环内酰胺类化合物的合成方法
WO2025106662A1 (en) * 2023-11-15 2025-05-22 Entasis Therapeutics, Inc. Preparation of boronic acid intermediates useful for the preparation of compounds for treating bacterial infections

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4607041A (en) * 1983-04-27 1986-08-19 Fisons Plc Antihypertensive 2-phenyl Hantzsch dihydropyridines
ATE177099T1 (de) 1993-12-29 1999-03-15 Pfizer Diazabicyclische neurokinin antagonisten
FR2812635B1 (fr) 2000-08-01 2002-10-11 Aventis Pharma Sa Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens
FR2825705B1 (fr) 2001-06-08 2005-05-20 Aventis Pharma Sa Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens
FR2835186B1 (fr) 2002-01-28 2006-10-20 Aventis Pharma Sa Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
FR2848210B1 (fr) 2002-12-06 2007-10-19 Aventis Pharma Sa Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens et inhibiteurs de beta-lactamases
US7439253B2 (en) 2002-12-06 2008-10-21 Novexel Heterocyclic compounds, their preparation and their use as medicaments, in particular as antibacterials and beta-lactamase inhibitors
FR2914923B1 (fr) 2007-04-12 2013-06-14 Novexel Nouveaux composes heterocycliques azotes,leur preparation et leur utilisation comme medicaments antibacteriens.
CN101918407B (zh) * 2008-01-18 2014-02-26 默沙东公司 β-内酰胺酶抑制剂
FR2930553B1 (fr) * 2008-04-29 2010-05-21 Novexel Composes azabicycliques, leur preparation et leur utilisation comme medicaments, notamment inhibiteurs de beta-lactamases
EP2921559A1 (en) 2008-06-19 2015-09-23 Astra Zeneca Holding France Use of (1r,2s,5r) 1,6-diazabicyclo [3.2.1]octane-2-carboxamide, 7-oxo-6-(sulfooxy)-, monosodium salt as a diagnostic reagent for detecting serine beta-lactamases
FR2936798B1 (fr) 2008-10-03 2012-09-28 Novexel Nouveaux composes heterocycliques azotes, leur preparation et leur utilisation comme medicaments antibacteriens.
FR2936951B1 (fr) 2008-10-10 2010-12-03 Novexel Nouvelles combinaisons de composes heterocycliques azotes antibacteriens avec d'autres composes antibacteriens et leur utilisation comme medicaments
FR2937034B1 (fr) 2008-10-10 2012-11-23 Novexel Nouveaux composes heterocycliques azotes, leur preparation et leur utilisation comme medicaments antibacteriens
FR2951171A1 (fr) 2009-10-09 2011-04-15 Novexel Nouveau sel de sodium d'un compose azabicyclique sous forme enantiomere cristallisee et nouvelles formes polymorphes et pseudopolymorphes ainsi que leur preparation
SMT201900482T1 (it) * 2010-04-20 2019-09-09 Fujifilm Toyama Chemical Co Ltd Derivato dell'acido idrossammico
RU2569059C2 (ru) 2011-07-26 2015-11-20 Вокхардт Лимитед Фармацевтические композиции, содержащие бета-лактамный антибиотик, сульбактам и ингибитор бета-лактамаз
JP5808860B2 (ja) 2011-07-26 2015-11-10 ウォックハート リミテッド スルバクタム及びベータ−ラクタマーゼインヒビターを含む医薬組成物
JP5666743B2 (ja) * 2011-08-27 2015-02-12 ウォックハート リミテッド 1,6−ジアザビシクロ[3,2,1]オクタン−7−オン誘導体および細菌感染の処置におけるそれらの使用
RU2570423C2 (ru) 2011-08-30 2015-12-10 Вокхардт Лимитед Производные 1,6-диазабицикло[3.2.1]октан-7-она и их применение при лечении бактериальных инфекций
ES2640520T3 (es) 2011-09-13 2017-11-03 Wockhardt Limited Compuestos que contienen nitrógeno y su uso
US8796257B2 (en) 2011-12-02 2014-08-05 Naeja Pharmaceutical Inc. Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors
US20150119363A1 (en) 2012-02-15 2015-04-30 Rempex Pharmaceuticals, Inc.. Methods of treating bacterial infections
US8969570B2 (en) 2012-03-30 2015-03-03 Cubist Pharmaceuticals, Inc. Beta-lactamase inhibitors
TW201343646A (zh) 2012-03-30 2013-11-01 Cubist Pharm Inc 異□唑β-內醯胺酶抑制劑
SG11201406123TA (en) 2012-03-30 2014-10-30 Cubist Pharm Inc 1,3,4-OXADIAZOLE AND 1,3,4-THIADIAZOLE β-LACTAMASE INHIBITORS
US8916709B2 (en) 2012-03-30 2014-12-23 Cubist Pharmaceuticals, Inc. 1,2,4-oxadiazole and 1,2,4-thiadiazole β-lactamase inhibitors
AR090539A1 (es) * 2012-04-02 2014-11-19 Astrazeneca Ab COMPUESTOS INHIBIDORES DE b LACTAMASA
WO2013180197A1 (ja) 2012-05-30 2013-12-05 Meiji Seikaファルマ株式会社 新規β-ラクタマーゼ阻害剤とその製造法
WO2014033560A1 (en) 2012-08-25 2014-03-06 Wockhardt Limited 1,6- diazabicyclo [3,2,1] octan- 7- one derivatives and their use in the treatment of bacterial infections
NZ706734A (en) 2012-09-03 2016-05-27 Wockhardt Ltd Pharmaceutical compositions useful for the treatment or control of bacterial infections
CN110302203A (zh) 2013-02-06 2019-10-08 辉瑞抗感染公司 用于治疗医院性肺炎的组合疗法
WO2014141132A1 (en) * 2013-03-14 2014-09-18 Naeja Pharmaceutical Inc. NEW HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS AND β-LACTAMASE INHIBITORS
DK3221313T3 (en) 2014-11-17 2019-04-08 Entasis Therapeutics Ltd COMBINATION THERAPY FOR TREATING INFECTIONS WITH RESISTANT BACTERIA
US10072006B2 (en) 2015-03-31 2018-09-11 Mutabilis Heterocyclic compounds and their use in preventing or treating bacterial infections
KR102537340B1 (ko) * 2016-09-16 2023-05-26 엔타시스 테라퓨틱스 리미티드 베타-락타마제 억제제 화합물
KR20230007830A (ko) * 2021-07-06 2023-01-13 현대자동차주식회사 고강성 저선팽창 열가소성 수지 조성물 및 이를 포함하는 성형체

Similar Documents

Publication Publication Date Title
JP2019532928A5 (enExample)
HRP20221217T1 (hr) Spojevi inhibitori beta-laktamaze
JP2016506960A5 (enExample)
JP2018507890A5 (enExample)
JP2015535847A5 (enExample)
JP2010524932A5 (enExample)
JP2010530372A5 (enExample)
JP2020507589A5 (enExample)
JP2018504437A5 (enExample)
RU2015100901A (ru) Производные эфира гетероарилкарбоновой кислоты
CY1113873T1 (el) Παραγωγα hydroxybenzamide σαν παραγοντες καταστολης της hsp90
JP2011526283A5 (enExample)
RU2017138972A (ru) Ингибиторы репликации вируса иммунодефицита человека
JP2013508297A5 (enExample)
EA201070872A1 (ru) Производные азабициклических карбоксамидов, их получение и их применение в терапии
JP2015537020A5 (enExample)
JP2016503052A5 (enExample)
HRP20090077B1 (hr) Modulatori farmakokinetičkih svojstava terapeutika
JP2014511891A5 (enExample)
JP2013544812A5 (enExample)
JP2016503797A5 (enExample)
JP2012505234A5 (enExample)
JP2017533263A5 (enExample)
TNSN06377A1 (en) Combinations of glycopyrrolate and beta2 adrenoceptor agonists
JP2015508092A5 (enExample)